The results demonstrated that the transcriptional activities of SREBF2 in the TP53 mutation group and DCIS were higher than that in the wild‐type TP53 group and DH, respectively (Figure 2G). This evidence concerns the gene SREBF2 and ductal breast carcinoma in situ.